Literature DB >> 26568904

The Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current Challenges.

Elizabeth D Ackerman1, Carolyn Ma2.   

Abstract

Mesh：

Year:  2015        PMID： 26568904      PMCID： PMC4642501     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN： 2165-8242


× No keyword cloud information.
  10 in total

1.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Authors:  Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

Review 2.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

3.  Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.

Authors:  Helen S Yee; Michael F Chang; Christine Pocha; Joseph Lim; David Ross; Timothy R Morgan; Alexander Monto
Journal:  Am J Gastroenterol       Date:  2012-05       Impact factor: 10.864

4.  Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Authors:  Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

5.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.

Authors:  Jianmeng Chen; Jeffry Florian; Wendy Carter; Russell D Fleischer; Thomas S Hammerstrom; Pravin R Jadhav; Wen Zeng; Jeffrey Murray; Debra Birnkrant
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

6.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

Authors:  Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

Review 7.  Hepatitis C virus therapy update 2013.

Authors:  Lisa C Casey; William M Lee
Journal:  Curr Opin Gastroenterol       Date:  2013-05       Impact factor: 3.287

8.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

10.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.

Authors:  Albert Do; Yash Mittal; AnnMarie Liapakis; Elizabeth Cohen; Hong Chau; Claudia Bertuccio; Dana Sapir; Jessica Wright; Carol Eggers; Kristine Drozd; Maria Ciarleglio; Yanhong Deng; Joseph K Lim
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.